Open AccessRhinovirus‐associated pulmonary exacerbations show a lack of FEV 1 improvement in children with cystic fibrosis
Author(s) -
Cousin Mathias,
Molinari Nicolas,
Foulongne Vincent,
Caimmi Davide,
Vachier Isabelle,
Abely Michel,
Chiron Raphael
Publication year - 2016
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12353
Subject(s) - rhinovirus , medicine , exacerbation , cystic fibrosis , pulmonary function testing , vital capacity , pulmonary fibrosis , respiratory system , lung , lung function , diffusing capacity
Background Respiratory viral infections lead to bronchial inflammation in patients with cystic fibrosis, especially during pulmonary exacerbations. The aim of this study was to determine the impact of viral‐associated pulmonary exacerbations in children with cystic fibrosis and failure to improve forced expiratory volume in 1 s ( FEV 1 ) after an appropriate treatment. Methods We lead a pilot study from January 2009 until March 2013. Children with a diagnosis of cystic fibrosis were longitudinally evaluated three times: at baseline (Visit 1), at the diagnosis of pulmonary exacerbation (Visit 2), and after exacerbation treatment (Visit 3). Nasal and bronchial samples were analyzed at each visit with multiplex viral respiratory PCR panel (qualitative detection of 16 viruses). Pulmonary function tests were recorded at each visit, in order to highlight a possible failure to improve them after treatment. Lack of improvement was defined by an increase in FEV 1 less than 5% between Visit 2 and Visit 3. Results Eighteen children were analyzed in the study. 10 patients failed to improve by more than 5% their FEV 1 between Visit 2 and Visit 3. Rhinovirus infection at Visit 2 or Visit 3 was the only risk factor significantly associated with such a failure ( OR , 12; 95% CI , 1·3–111·3), P = 0·03. Conclusions Rhinovirus infection seems to play a role in the FEV 1 recovery after pulmonary exacerbation treatment in children with cystic fibrosis. Such an association needs to be confirmed by a large‐scale study because this finding may have important implications for pulmonary exacerbation management.